Trial Outcomes & Findings for Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease (NCT NCT01696396)

Last Updated: 2019-06-27

Results Overview

Remission was defined as a Crohn's Disease Activity Index (CDAI) score \< 150 at week 8. The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity. The remission rate (percentage of participants with remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline CDAI Score (adjusted remission rate).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

254 participants

Primary outcome timeframe

Week 8

Results posted on

2019-06-27

Participant Flow

This study was conducted at 84 centers in Canada, European Union, and the United States. Participants were enrolled from 04 December 2012 to 30 September 2014. The study consisted of a 24-week double-blind treatment period, a 108-week open-label treatment period, and a safety follow-up period.

Participants were to be randomly assigned in a 2:1:2:1 ratio to 1 of 4 treatment groups. Due to a misalignment error, some participants were erroneously assigned to incorrect treatment resulting in a final randomization ratio different from that originally stipulated in the protocol.

Participant milestones

Participant milestones
Measure	Placebo/Abrilumab 210 mg Q3M Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.	Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 210 mg/Abrilumab 210 mg Q3M Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.
Overall Study STARTED	100	27	85	42
Overall Study Received Study Drug	98	26	84	41
Overall Study Entered Open-label Period	84	21	75	37
Overall Study COMPLETED	69	20	59	28
Overall Study NOT COMPLETED	31	7	26	14

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo/Abrilumab 210 mg Q3M Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.	Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.	Abrilumab 210 mg/Abrilumab 210 mg Q3M Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24. During the open-label period, participants received abrilumab 210 mg once every 3 months for 108 weeks.
Overall Study Withdrawal by Subject	19	5	19	11
Overall Study Decision by Sponsor	3	1	2	2
Overall Study Lost to Follow-up	9	1	4	1
Overall Study Death	0	0	1	0

Baseline Characteristics

Participants with available data

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=100 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=27 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=85 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=42 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Total n=254 Participants Total of all reporting groups
Age, Continuous	36.2 years STANDARD_DEVIATION 11.2 • n=100 Participants	38.9 years STANDARD_DEVIATION 14.2 • n=27 Participants	35.6 years STANDARD_DEVIATION 11.8 • n=85 Participants	36.5 years STANDARD_DEVIATION 9.4 • n=42 Participants	36.4 years STANDARD_DEVIATION 11.4 • n=254 Participants
Age, Customized 18 - 64 years	99 Participants n=100 Participants	27 Participants n=27 Participants	85 Participants n=85 Participants	42 Participants n=42 Participants	253 Participants n=254 Participants
Age, Customized ≥ 65 years	1 Participants n=100 Participants	0 Participants n=27 Participants	0 Participants n=85 Participants	0 Participants n=42 Participants	1 Participants n=254 Participants
Sex: Female, Male Female	58 Participants n=100 Participants	12 Participants n=27 Participants	51 Participants n=85 Participants	23 Participants n=42 Participants	144 Participants n=254 Participants
Sex: Female, Male Male	42 Participants n=100 Participants	15 Participants n=27 Participants	34 Participants n=85 Participants	19 Participants n=42 Participants	110 Participants n=254 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=100 Participants	1 Participants n=27 Participants	0 Participants n=85 Participants	1 Participants n=42 Participants	2 Participants n=254 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	100 Participants n=100 Participants	26 Participants n=27 Participants	85 Participants n=85 Participants	41 Participants n=42 Participants	252 Participants n=254 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=100 Participants	0 Participants n=27 Participants	0 Participants n=85 Participants	0 Participants n=42 Participants	0 Participants n=254 Participants
Race/Ethnicity, Customized Asian	0 Participants n=100 Participants	0 Participants n=27 Participants	0 Participants n=85 Participants	1 Participants n=42 Participants	1 Participants n=254 Participants
Race/Ethnicity, Customized Black or African American	2 Participants n=100 Participants	0 Participants n=27 Participants	0 Participants n=85 Participants	1 Participants n=42 Participants	3 Participants n=254 Participants
Race/Ethnicity, Customized White	97 Participants n=100 Participants	26 Participants n=27 Participants	82 Participants n=85 Participants	40 Participants n=42 Participants	245 Participants n=254 Participants
Race/Ethnicity, Customized Other	1 Participants n=100 Participants	1 Participants n=27 Participants	3 Participants n=85 Participants	0 Participants n=42 Participants	5 Participants n=254 Participants
Any Prior Anti-Tumor Necrosis Factor (TNF) Use Yes	80 Participants n=100 Participants	21 Participants n=27 Participants	67 Participants n=85 Participants	33 Participants n=42 Participants	201 Participants n=254 Participants
Any Prior Anti-Tumor Necrosis Factor (TNF) Use No	20 Participants n=100 Participants	6 Participants n=27 Participants	18 Participants n=85 Participants	9 Participants n=42 Participants	53 Participants n=254 Participants
Enrollment Prior to Protocol Amendment 3 Yes	44 Participants n=100 Participants	0 Participants n=27 Participants	29 Participants n=85 Participants	16 Participants n=42 Participants	89 Participants n=254 Participants
Enrollment Prior to Protocol Amendment 3 No	56 Participants n=100 Participants	27 Participants n=27 Participants	56 Participants n=85 Participants	26 Participants n=42 Participants	165 Participants n=254 Participants
Duration of Crohn's Diease	11.07 years STANDARD_DEVIATION 8.33 • n=100 Participants	12.58 years STANDARD_DEVIATION 9.55 • n=27 Participants	10.69 years STANDARD_DEVIATION 7.75 • n=85 Participants	11.31 years STANDARD_DEVIATION 7.54 • n=42 Participants	11.15 years STANDARD_DEVIATION 8.12 • n=254 Participants
Crohn's Disease Activity Index (CDAI) Score	303.8 units on a scale STANDARD_DEVIATION 63.2 • n=99 Participants • Participants with available data	310.0 units on a scale STANDARD_DEVIATION 83.5 • n=27 Participants • Participants with available data	314.0 units on a scale STANDARD_DEVIATION 60.4 • n=84 Participants • Participants with available data	319.3 units on a scale STANDARD_DEVIATION 67.5 • n=42 Participants • Participants with available data	310.5 units on a scale STANDARD_DEVIATION 65.3 • n=252 Participants • Participants with available data

PRIMARY outcome

Timeframe: Week 8

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both unadjusted and adjusted remission rates were calculated using non-responder imputation, where participants with a missing CDAI Score at week 8 were counted as non-responders.

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Remission at Week 8 Unadjusted remission rate	13.3 percentage of participants	23.1 percentage of participants	14.3 percentage of participants	19.5 percentage of participants
Percentage of Participants With Remission at Week 8 Adjusted remission rate	12.8 percentage of participants	23.1 percentage of participants	14.4 percentage of participants	21.9 percentage of participants

SECONDARY outcome

Timeframe: Week 12

Remission was defined as a Crohn's Disease Activity Index (CDAI) score \< 150. The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity. The remission rate (percentage of participants with remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline CDAI Score (adjusted remission rate).

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Remission at Week 12 Unadjusted remission rate	18.1 percentage of participants	33.3 percentage of participants	25.3 percentage of participants	27.0 percentage of participants
Percentage of Participants With Remission at Week 12 Adjusted remission rate	20.1 percentage of participants	43.8 percentage of participants	31.0 percentage of participants	34.8 percentage of participants

SECONDARY outcome

Timeframe: Baseline and week 12

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both unadjusted and adjusted response rates were calculated using non-responder imputation, where participants with a missing CDAI Score at week 12 were counted as non-responders.

Response was defined as either remission (a CDAI score \< 150) or a decrease from baseline in the CDAI score of ≥ 100 points. The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity. The response rate (percentage of participants with response) was calculated based on observed data (unadjusted response rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline CDAI score (adjusted response rate).

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Response at Week 12 Unadjusted response rate	27.7 percentage of participants	41.7 percentage of participants	45.3 percentage of participants	43.2 percentage of participants
Percentage of Participants With Response at Week 12 Adjusted response rate	35.3 percentage of participants	50.4 percentage of participants	55.1 percentage of participants	50.9 percentage of participants

SECONDARY outcome

Timeframe: Baseline and week 8

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Response at Week 8 Unadjusted response rate	26.4 percentage of participants	33.3 percentage of participants	42.9 percentage of participants	30.6 percentage of participants
Percentage of Participants With Response at Week 8 Adjusted response rate	30.6 percentage of participants	33.8 percentage of participants	46.6 percentage of participants	32.6 percentage of participants

SECONDARY outcome

Timeframe: Week 12 and week 24

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Both unadjusted and adjusted sustained remission rates were calculated using non-responder imputation, where participants with missing CDAI scores at week 12 or week 24 were counted as non-responders.

Remission was defined as a Crohn's Disease Activity Index (CDAI) score \< 150. Sustained remission was defined as achieving the criteria for remission at both week 12 and week 24. The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity. The remission rate (percentage of participants with sustained remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline CDAI Score (adjusted remission rate).

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Sustained Remission at Both Week 12 and Week 24 Unadjusted remission rate	8.2 percentage of participants	19.2 percentage of participants	11.9 percentage of participants	17.1 percentage of participants
Percentage of Participants With Sustained Remission at Both Week 12 and Week 24 Adjusted remission rate	9.0 percentage of participants	25.0 percentage of participants	14.0 percentage of participants	21.7 percentage of participants

SECONDARY outcome

Timeframe: Week 8 and week 24

Remission was defined as a Crohn's Disease Activity Index (CDAI) score \< 150. Sustained remission was defined as achieving the criteria for remission at both week 8 and week 24. The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity. The remission rate (percentage of participants with sustained remission) was calculated based on observed data (unadjusted remission rate) and also after applying a logistic regression model including the factors of treatment group, stratification factors (prior anti-TNF use and pre- versus post-Protocol Amendment 3) and baseline CDAI Score (adjusted remission rate).

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Percentage of Participants With Sustained Remission at Both Week 8 and Week 24 Unadjusted remission rate	7.1 percentage of participants	15.4 percentage of participants	9.5 percentage of participants	12.2 percentage of participants
Percentage of Participants With Sustained Remission at Both Week 8 and Week 24 Adjusted remission rate	5.9 percentage of participants	14.3 percentage of participants	8.7 percentage of participants	12.7 percentage of participants

SECONDARY outcome

Timeframe: Baseline and week 12

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Missing data were handled using the inverse probability weighting (IPW) method.

The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity.

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Change From Baseline in CDAI Score at Week 12	-55.32 units on a scale Standard Error 11.41	-92.16 units on a scale Standard Error 21.85	-97.41 units on a scale Standard Error 12.92	-96.11 units on a scale Standard Error 22.78

SECONDARY outcome

Timeframe: Baseline and week 8

Population: The full analysis set includes all randomized participants who received at least 1 dose of study drug. Missing data were handled using the inverse probability weighting (IPW) method.

Outcome measures

Outcome measures
Measure	Placebo n=98 Participants Participants randomized to receive placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 21 mg Q4W n=26 Participants Participants randomized to receive 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24 during the double-blind treatment period.	Abrilumab 70 mg Q4W n=84 Participants Participants randomized to receive 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	Abrilumab 210 mg n=41 Participants Participants randomized to receive a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.
Change From Baseline in CDAI Score at Week 8	-64.05 units on a scale Standard Error 9.62	-80.42 units on a scale Standard Error 20.86	-91.52 units on a scale Standard Error 11.78	-87.64 units on a scale Standard Error 19.89

Adverse Events

DB Period: Placebo

Serious events: 14 serious events

Other events: 61 other events

Deaths: 0 deaths

DB Period: Abrilumab 21 mg Q4W

Serious events: 7 serious events

Other events: 14 other events

Deaths: 0 deaths

DB Period: Abrilumab 70 mg Q4W

Serious events: 13 serious events

Other events: 48 other events

Deaths: 0 deaths

DB Period: Abrilumab 210 mg

Serious events: 6 serious events

Other events: 27 other events

Deaths: 0 deaths

OL Period: Placebo/Abrilumab 210 mg Q3M

Serious events: 24 serious events

Other events: 61 other events

Deaths: 0 deaths

OL Period: Abrilumab 21 mg Q4W/210 mg Q3M

Serious events: 3 serious events

Other events: 16 other events

Deaths: 0 deaths

OL Period: Abrilumab 70 mg Q4W/210 mg Q3M

Serious events: 19 serious events

Other events: 55 other events

Deaths: 0 deaths

Period: Abrilumab 210 mg/210 mg Q3M

Serious events: 12 serious events

Other events: 28 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	DB Period: Placebo n=98 participants at risk Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind (DB) treatment period.	DB Period: Abrilumab 21 mg Q4W n=25 participants at risk Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 70 mg Q4W n=85 participants at risk Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 210 mg n=41 participants at risk Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	OL Period: Placebo/Abrilumab 210 mg Q3M n=84 participants at risk Participants who received placebo during the double-blind treatment period received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks during the open-label (OL) treatment period.	OL Period: Abrilumab 21 mg Q4W/210 mg Q3M n=20 participants at risk During the open-label period, participants who received 21 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks.	OL Period: Abrilumab 70 mg Q4W/210 mg Q3M n=76 participants at risk Participants who received 70 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.	Period: Abrilumab 210 mg/210 mg Q3M n=37 participants at risk Participants who received 210 mg abrilumab during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.
Blood and lymphatic system disorders Anaemia	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Acute myocardial infarction	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Cardiac arrest	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Myocardial infarction	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Myocardial ischaemia	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal hernia	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Anal fistula	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Chronic gastritis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Constipation	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Crohn's disease	9.2% 9/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.5% 3/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.7% 9/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.5% 8/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.2% 6/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Enteritis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Enterocolonic fistula	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Ileal stenosis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Ileus	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Large intestine perforation	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Small intestinal obstruction	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.5% 3/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Adverse drug reaction	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Chills	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Influenza like illness	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Multiple organ dysfunction syndrome	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pyrexia	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Hepatobiliary disorders Bile duct stone	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Hepatobiliary disorders Biliary colic	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Hepatobiliary disorders Hepatic function abnormal	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Abdominal abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Abdominal wall abscess	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Abscess intestinal	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Anal abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.9% 3/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Appendicitis perforated	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Clostridium difficile colitis	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Clostridium difficile infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Erysipelas	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Escherichia sepsis	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Escherichia urinary tract infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations External ear cellulitis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis viral	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Influenza	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Intrauterine infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Necrotising fasciitis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pelvic abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Perineal abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pneumonia parainfluenzae viral	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Postoperative wound infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Psoas abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Retroperitoneal abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Septic shock	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Tubo-ovarian abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Urinary tract infection	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Vulval abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Anastomotic leak	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Clavicle fracture	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Intestinal anastomosis complication	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Dehydration	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic myeloid leukaemia	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Cerebrovascular accident	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Transient ischaemic attack	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Nephritis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Nephrolithiasis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Reproductive system and breast disorders Cervical dysplasia	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Social circumstances Aborted pregnancy	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Surgical and medical procedures Cholecystectomy	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Surgical and medical procedures Ileocolectomy	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Surgical and medical procedures Scoliosis surgery	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Other adverse events

Other adverse events
Measure	DB Period: Placebo n=98 participants at risk Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind (DB) treatment period.	DB Period: Abrilumab 21 mg Q4W n=25 participants at risk Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 70 mg Q4W n=85 participants at risk Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	DB Period: Abrilumab 210 mg n=41 participants at risk Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24 during the double-blind treatment period.	OL Period: Placebo/Abrilumab 210 mg Q3M n=84 participants at risk Participants who received placebo during the double-blind treatment period received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks during the open-label (OL) treatment period.	OL Period: Abrilumab 21 mg Q4W/210 mg Q3M n=20 participants at risk During the open-label period, participants who received 21 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks.	OL Period: Abrilumab 70 mg Q4W/210 mg Q3M n=76 participants at risk Participants who received 70 mg abrilumab Q4W during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.	Period: Abrilumab 210 mg/210 mg Q3M n=37 participants at risk Participants who received 210 mg abrilumab during the DB treatment period received abrilumab 210 mg once every 3 months for 108 weeks during the open-label period.
Blood and lymphatic system disorders Anaemia	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.6% 3/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.9% 3/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Ear and labyrinth disorders Tinnitus	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal distension	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain	9.2% 9/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.4% 8/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.7% 9/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.2% 10/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Anal fistula	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.6% 3/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Constipation	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Crohn's disease	8.2% 8/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.7% 14/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	15.8% 12/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 3/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Diarrhoea	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 4/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.0% 5/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.6% 5/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Gastrointestinal fistula	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Nausea	8.2% 8/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 7/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.6% 5/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.8% 4/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Oral discomfort	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Proctalgia	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Toothache	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Vomiting	3.1% 3/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.5% 3/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.0% 5/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Asthenia	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.0% 5/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Fatigue	4.1% 4/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.6% 3/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Influenza like illness	4.1% 4/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 4/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.0% 5/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.2% 7/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 3/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Malaise	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Oedema peripheral	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pain	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pyrexia	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 4/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 4/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	15.0% 3/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.5% 5/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Hepatobiliary disorders Cholelithiasis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Seasonal allergy	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Anal abscess	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.3% 4/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Bronchitis	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.5% 3/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 4/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Cellulitis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Clostridium difficile infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Conjunctivitis	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Fungal infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis	6.1% 6/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.5% 3/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.2% 7/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis viral	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Herpes zoster	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Influenza	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 4/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.2% 10/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.2% 6/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Nasopharyngitis	11.2% 11/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.2% 7/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 12/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	18.4% 14/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.2% 6/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Psoas abscess	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Sinusitis	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.9% 3/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Upper respiratory tract infection	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.2% 7/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 6/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 3/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Urinary tract infection	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 6/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.6% 3/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Viral infection	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.9% 3/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Fall	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood iron decreased	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood urea increased	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Clostridium test positive	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Magnesium deficiency	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Vitamin B12 deficiency	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Vitamin D deficiency	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Zinc deficiency	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Arthralgia	10.2% 10/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.4% 8/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.0% 5/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.2% 7/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.5% 5/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Arthritis	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Back pain	4.1% 4/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.9% 3/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Muscle spasms	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Myalgia	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.3% 3/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Dizziness	7.1% 7/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 4/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Headache	11.2% 11/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.1% 12/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	19.5% 8/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 7/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	15.0% 3/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 3/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Memory impairment	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Nervous system disorder	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Paraesthesia	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.2% 7/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 4/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Depression	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 2/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 3/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Insomnia	3.1% 3/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.6% 3/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.6% 5/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Restlessness	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Dysuria	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Urinary incontinence	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Dyspnoea	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	3.1% 3/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 4/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.9% 2/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 4/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.1% 3/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Acne	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Hyperhidrosis	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Pruritus	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 2/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Rash	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 6/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.6% 2/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.8% 4/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Rash maculo-papular	1.0% 1/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.7% 1/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Surgical and medical procedures Female sterilisation	0.00% 0/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.0% 1/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Hypertension	2.0% 2/98 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/25 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/85 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 1/41 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.2% 1/84 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/20 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.3% 1/76 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.4% 2/37 • From first dose of study drug to week 24 in the double-blind period and from first dose of study drug in the open-label period to 12 weeks after last dose in the open-label period (up to 108 weeks). One participant randomized to the 21 mg abrilumab treatment group received 70 mg abrilumab in error and is counted in the Abrilumab 70 mg group for safety analyses in both treatment periods. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
Publication restrictions are in place

Restriction type: OTHER